Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hideo Kubodera is active.

Publication


Featured researches published by Hideo Kubodera.


Bioorganic & Medicinal Chemistry Letters | 2013

6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.

Fumiaki Uehara; Aya Shoda; Keiichi Aritomo; Kenji Fukunaga; Kazutoshi Watanabe; Ryoichi Ando; Masaki Shinoda; Hiroaki Ueno; Hideo Kubodera; Shinji Sunada; Kenichi Saito; Takahide Kaji; Shoichi Asano; Jun-ichi Eguchi; Satoshi Yuki; Shinji Tanaka; Yukimi Yoneyama

The discovery of a series of 6-(4-pyridyl)pyrimidin-4(3H)-ones derived from a hit compound with low molecular weight and sufficient chemical space is reported. Transformation of substituents led to subnanomolar potent inhibitors with in vivo tau phoshorylation lowering activity.


PLOS ONE | 2015

The 4'-hydroxyl group of resveratrol is functionally important for direct activation of PPARα.

Yoshie Takizawa; Rieko Nakata; Kiyoshi Fukuhara; Hiroshi Yamashita; Hideo Kubodera; Hiroyasu Inoue

Long-term moderate consumption of red wine is associated with a reduced risk of developing lifestyle-related diseases such as cardiovascular disease and cancer. Therefore, resveratrol, a constituent of grapes and various other plants, has attracted substantial interest. This study focused on one molecular target of resveratrol, the peroxisome proliferator activated receptor α (PPARα). Our previous study in mice showed that resveratrol-mediated protection of the brain against stroke requires activation of PPARα; however, the molecular mechanisms involved in this process remain unknown. Here, we evaluated the chemical basis of the resveratrol-mediated activation of PPARα by performing a docking mode simulation and examining the structure-activity relationships of various polyphenols. The results of experiments using the crystal structure of the PPARα ligand-binding domain and an analysis of the activation of PPARα by a resveratrol analog 4-phenylazophenol (4-PAP) in vivo indicate that the 4′-hydroxyl group of resveratrol is critical for the direct activation of PPARα. Activation of PPARα by 5 μM resveratrol was enhanced by rolipram, an inhibitor of phosphodiesterase (PDE) and forskolin, an activator of adenylate cyclase. We also found that resveratrol has a higher PDE inhibitory activity (IC50 = 19 μM) than resveratrol analogs trans-4-hydroxystilbene and 4-PAP (IC50 = 27-28 μM), both of which has only 4′-hydroxyl group, indicating that this 4′-hydroxyl group of resveratrol is not sufficient for the inhibition of PDE. This result is consistent with that 10 μM resveratrol has a higher agonistic activity of PPARα than these analogs, suggesting that there is a feedforward activation loop of PPARα by resveratrol, which may be involved in the long-term effects of resveratrol in vivo.


Molecules | 2010

Lead Generation and Optimization Based on Protein-Ligand Complementarity

Koji Ogata; Tetsu Isomura; Shinji Kawata; Hiroshi Yamashita; Hideo Kubodera

This work proposes a computational procedure for structure-based lead generation and optimization, which relies on the complementarity of the protein-ligand interactions. This procedure takes as input the known structure of a protein-ligand complex. Retaining the positions of the ligand heavy atoms in the protein binding site it designs structurally similar compounds considering all possible combinations of atomic species (N, C, O, CH3, NH, etc). Compounds are ranked based on a score which incorporates energetic contributions evaluated using molecular mechanics force fields. This procedure was used to design new inhibitor molecules for three serine/threonine protein kinases (p38 MAP kinase, p42 MAP kinase (ERK2), and c-Jun N-terminal kinase 3 (JNK3)). For each enzyme, the calculations produce a set of potential inhibitors whose scores are in agreement with IC50 data and Ki values. Furthermore, the native ligands for each protein target, scored within the five top-ranking compounds predicted by our method, one of the top-ranking compounds predicted to inhibit JNK3 was synthesized and his inhibitory activity confirmed against ATP hydrolysis. Our computational procedure is therefore deemed to be a useful tool for generating chemically diverse molecules active against known target proteins.


Biophysical Chemistry | 2013

Prediction of the binding affinity of compounds with diverse scaffolds by MP-CAFEE

Okimasa Okada; Hiroshi Yamashita; Kei Takedomi; Satoshi Ono; Shinji Sunada; Hideo Kubodera

Accurate methods to predict the binding affinities of compounds for target molecules are powerful tools in structure-based drug design (SBDD). A recently developed method called massively parallel computation of absolute binding free energy with a well-equilibrated system (MP-CAFEE) successfully predicted the binding affinities of compounds with relatively similar scaffolds. We investigate the applicability of MP-CAFEE for predicting the affinity of compounds having more diverse scaffolds for the target p38α, a mitogen-activated protein kinase. The calculated and experimental binding affinities correlate well, showing that MP-CAFEE can accurately rank the compounds with diverse scaffolds. We propose a method to determine the optimal number of sampling runs with respect to a predefined level of accuracy, which is established according to the stage in the SBDD process being considered. The optimal number of sampling runs for two key stages-lead identification and lead optimization-is estimated to be five and eight or more, respectively, in our model system using Cochrans sample size formula.


Biochemical and Biophysical Research Communications | 2010

ASK3, a novel member of the apoptosis signal-regulating kinase family, is essential for stress-induced cell death in HeLa cells

Takahide Kaji; Sawako Yoshida; Kunji Kawai; Yoshihiro Fuchigami; Wakako Watanabe; Hideo Kubodera; Toshimitsu Kishimoto


Qsar & Combinatorial Science | 2007

A Quantitative Approach to the Estimation of Chemical Space from a Given Geometry by the Combination of Atomic Species

Koji Ogata; Tetsu Isomura; Hiroshi Yamashita; Hideo Kubodera


Archive | 2004

Novel protein and dna coding for the same

Takao Isogai; Tomoyasu Sugiyama; Tetsuji Otsuki; Ai Wakamatsu; Takahide Kaji; Toshimitsu Kishimoto; Wakako Watanabe; Hideo Kubodera


Genome Informatics | 2002

Development of a Protein-Ligand Interaction Database, ProLINT, and Its Application to QSAR Analysis

K. Kitajima; Hideo Kubodera; Shandar Ahmad; Shinji Sunada; Samuel Selvaraj; Jianghong An; Akinori Sarai


Genome Informatics | 2003

Protein-Ligand Interactions: ProLINT Database and QSAR Analysis

Shandar Ahmad; K. Kitajima; Samuel Selvaraj; Hideo Kubodera; Shinji Sunada; Jianghong An; Akinori Sarai


Archive | 2004

Nouvelle proteine et adn la codant

Takao Isogai; Tomoyasu Sugiyama; Tetsuji Otsuki; Ai Wakamatsu; Takahide Kaji; Toshimitsu Kishimoto; Wakako Watanabe; Hideo Kubodera

Collaboration


Dive into the Hideo Kubodera's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

K. Kitajima

Kyushu Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Takahide Kaji

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar

Jianghong An

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akinori Sarai

Beckman Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tetsuji Otsuki

Taisho Pharmaceutical Co.

View shared research outputs
Researchain Logo
Decentralizing Knowledge